Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial-Reference-Cited by-同舟云学术

Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial

Published:2021-06-01 Issue:2 Volume:87 Page:801-805
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Kumar Princy,Johnson Margaret,Molina Jean-Michel,Rizzardini Giuliano,Cahn Pedro,Bickel Markus,Wan Hong,Xu Zhi Jin,Morais Cristiana,Sklar Peter,Greaves Wayne,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference14 articles.

1. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways;Feng;Antimicrob Agents Chemother.,2015

2. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects;Behm;Clin Drug Investig.,2017

3. Results of a doravirine-atorvastatin drug-drug interaction study;Khalilieh;Antimicrob Agents Chemother.,2017

4. Effect of doravirine (MK-1439) on the pharmacokinetics of an oral contraceptive (ethinyl estradiol and levonorgestrel);Anderson;Rev Antivir Ther Infect Dis.,2015

5. A study to evaluate doravirine pharmacokinetics when co-administered with acid-reducing agents;Khalilieh;J Clin Pharmacol.,2019

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review;Infectious Disease Reports;2024-09-01

2. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study;The Lancet HIV;2024-09

3. Experienced PLWH switching to DOR/3TC/TDF in outpatient setting: real-word data on tolerability and Cost Savings from an Italian multicenter cohort.;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-04-12

4. Improvement in insulin sensitivity after switching from an integrase inhibitor‐based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain;HIV Medicine;2024-04-03

5. The best place for doravirine;The Lancet HIV;2024-02